6533b7d0fe1ef96bd125b81e
RESEARCH PRODUCT
Multicentric study on the beta-blocker use and relation with exacerbations in COPD
Luis Puente-maestuLuis Puente-maestuEduardo Márquez-martínCruz GonzálezAntonia FusterMyriam CalleCarmen CaleroPedro Jorge Marcos-rodriguezJuan Luis Rodríguez-hermosaGema Tirado-condeMyriam AburtoPatricia SobradilloBernardino AlcazarÁNgel Ortega-gonzálezRosa Malo De Molinasubject
MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationAdrenergic beta-AntagonistsComorbidityCoronary Artery DiseaseEmergency treatmentSeverity of Illness IndexCoronary artery diseasePulmonary Disease Chronic ObstructiveRisk FactorsInternal medicineDiabetes mellitusOxygen therapymedicineHumansMyocardial infarctioneducationBeta blockerAgedAged 80 and overHeart Failureeducation.field_of_studyCOPDbusiness.industryAdverse effectsChronic obstructive pulmonary diseaseMiddle Agedmedicine.diseaseDrug UtilizationBronchodilator AgentsMyocardial infarctionCross-Sectional StudiesSpainHeart failureCardiologyFemalebusinessEmergency Service Hospitaldescription
SummaryChronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart failure (CHF) or coronary artery disease (CAD). In spite of the recommendation to use beta-blockers (BB) they are likely under-prescribed to patients with concurrent COPD and heart diseases. To find out the prevalence of use of BB, 256 COPD patients were consecutively recruited by pulmonary physicians from 14 hospitals in 7 regions of Spain in their outpatient offices if they had a diagnosis of COPD, were not on long-term oxygen therapy, had CHF or CAD, and met the criteria for BB treatment.In patients with indication 58% (95%CI, 52–64%) of the COPD patients and 97% of the non-COPD patients were on BB (p 70, OR 2.19 (1.24–3.86) use of long-acting beta2-agonists OR = 2.18 (1.29–3.68), previous episodes of left ventricular failure OR 2.27 (1.19–4.33) and diabetes, OR = 1.82 (1.08–3.38).We conclude that, according to what is recommended by current guidelines, BB are still under-prescribed in COPD patients. COPD patients with CHF or CAD using BB suffer fewer exacerbations and visits to the ER. GOLD stage, use of long-acting beta2-agonists, baseline heart rate and comorbidities are also risk factors for exacerbations in this population.
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-01 | Respiratory Medicine |